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Abstract Transforming growth factor-K (TGF-K) increased the
expression of 12-lipoxygenase activity in a time-dependent
manner in human epidermoid carcinoma A431 cells. The increase
of 12-lipoxygenase activity was accompanied by an increase in
12-lipoxygenase mRNA. The effect of TGF-K on the promoter
activation of 12-lipoxygenase gene was analyzed by using the
luciferase fusion vectors. A dose-dependent effect of TGF-K on
the reporter activity was observed, which paralleled with its effect
on enzyme activity. Transient transfection with a series of 5P-
deleted constructs showed that the 5P-flanking region spanning
from 3224 to 3100 bp from translation starting site played an
important role for TGF-K response. Site-directed mutagenesis
and gel mobility shift assay indicated that two Sp1 binding
sequences residing at 3158 to 3150 bp and 3123 to 3114 bp
were responsible for the TGF-K in activation of human 12-
lipoxygenase gene transcription. Expression of Sp1, but not Sp3,
stimulated the promoter activity of 12-lipoxygenase in SL2 cells,
indicating that the binding of Sp1 with Sp1 binding sequences
played a significant role in the regulation of 12-lipoxygenase
gene.
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1. Introduction
Arachidonate 12-lipoxygenase (arachidonate: oxygen 12-
oxidoreductase, EC 1.13.11.31) in the platelet is the ¢rst mam-
malian lipoxygenase discovered [1,2]. It catalyzes the trans-
formation of arachidonic acid into 12(S)-hydroperoxyeicosa-
tetraenoic acid, which is subsequently converted to 12(S)-
hydroxyeicosatetraenoic acid (12(S)-HETE) by a gluta-
thione-dependent peroxidase [3]. The human platelet-type
12-lipoxygenase is also found in human erythroleukemia cell
[4,5], epidermal cell [6], epidermoid carcinoma A431 cell [7]
and keratinocyte [8].
In comparison, the biological activities of 12(S)-HETE are
less well understood than the metabolites formed by 5-lipox-
ygenase catalysis. However, 12(S)-HETE may play a signi¢-
cant role in the pathogenesis of some epidermal and epithelial
in£ammation. In the psoriatic lesions, a markedly elevated 12-
HETE was found whereas the levels of prostaglandins E2 and
F2K were only minimally elevated [9]. Although 12-HETE is
less potent than leukotriene B4 with regard to neutrophil ac-
tivation, it has been shown to be a chemotactic stimulus for
epidermal cells [10]. In vivo, moreover, in guinea pig skin,
unequivocal growth promotion in addition to the in£amma-
tion reaction was observed upon 12-HETE activation [11].
Therefore, high tissue concentration of 12(S)-HETE contrib-
utes to the in£ammatory change and the abnormal epidermal
hyperproliferation in the development of a psoriatic plaque.
Furthermore, Hussain et al. [8] recently found an overexpres-
sion of the human platelet-type 12-lipoxygenase in germinal
layer keratinocyte in psoriasis.
Keratinocytes, in vitro, can be induced to synthesize trans-
forming growth factor-K (TGF-K) [12], which is a natural
ligand for epidermal growth factor (EGF) receptors. Both
EGF receptors and TGF-K are overexpressed in psoriatic epi-
dermis [13,14]. In the study of the regulation of 12-lipoxyge-
nase expression in human epidermoid carcinoma A431 cells,
which overexpress EGF receptors, we found that EGF ap-
proximately doubled the mRNA level and enzyme activity
[7]. In the present study, the direct e¡ect of TGF-K on the
expression of 12-lipoxygenase in A431 cells was investigated.
The results indicate that TGF-K induced the expression of 12-
lipoxygenase, and activated the promoter of 12-lipoxygenase
gene in the same fashion as EGF.
2. Materials and methods
2.1. Materials
Human TGF-K was purchased from Collaborative Research (Bed-
ford, MA, USA). [1-14C]arachidonic acid (58 mCi/mmol), [K-
32P]dCTP (3000 Ci/mmol) and [Q-32P]ATP (5000 Ci/mmol), mega-
prime DNA labeling system, and nylon membrane (Hybond-N)
were purchased from Amersham (Little Chalfond, Bucks, UK). Bo-
vine serum albumin, polyvinyl alcohol, HEPES and o-nitrophenyl L-
galactosidase were from Sigma (St. Louis, MO, USA). The luciferase
assay system was from Promega (Madison, WI, USA). Qiagen-tip 100
was from Qiagen (Hilden, Germany). Luciferase plasmid pXP-1 was a
gift of Dr. T. Sakai (Kyoto Prefecture University of Medicine, Kyoto,
Japan). L-Galactosidase plasmid (CMVL) was from Clontech Labo-
ratories (Palo Alto, CA, USA). pCMV-Sp1 and pCMV-Sp3 were
provided by Dr. Gunstram Suske (University of Marburg, Germany).
Lipofectamine, Dulbecco’s modi¢ed Eagle’s medium, Opti-MEM me-
dium and Schneider’s Drosophila medium were obtained from Gibco
BRL (Grand Island, NY, USA). Fetal bovine serum was from Hy-
clone Laboratories (Logan, UT, USA).
2.2. Cell culture
Human epidermoid carcinoma A431 cells were grown at 37‡C in
air/CO2 (19:1) in 10-cm plastic dishes containing 10 ml of Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% (v/v) fetal bovine
serum, 100 Wg/ml streptomycin and 100 i.u./ml penicillin. Schneider
line 2 (SL2) cells were grown at 25‡C in a 10-cm plastic dish contain-
ing 10 ml of Schneider’s Drosophila medium supplemented with 10%
(v/v) fetal bovine serum.
2.3. Treatment of cells with TGF-K
The con£uent cells were treated with 50 ng/ml TGF-K in serum-free
medium. After 30 min of TGF-K treatment, the medium was re-
moved. The cells were further cultured in fresh serum-free medium
up to 18 h unless stated otherwise. No signi¢cant change in cell via-
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bility and morphology was observed under this experimental condi-
tion.
2.4. Assay of the microsomal 12-lipoxygenase activity
The preparation of microsome and analysis of 12-lipoxygenase ac-
tivity were performed as previously described [15]. The assay mixture
contained 8.5 WM [1-14C]arachidonic acid (0.1 WCi) and an appropri-
ate amount of microsomes in a ¢nal volume of 0.2 ml. After extrac-
tion with 1 ml of ethyl acetate, the organic layer was evaporated.
Residues were dissolved in ethanol and applied to thin-layer chroma-
tography plates. The formation of [1-14C]12(S)-HETE was quanti-
tated by a System 2000 Imaging Scanner (BIOSCAN).
2.5. RNA blot analysis
RNA blot analysis was performed as previously described [15].
Total RNA was isolated from A431 cells by the guanidine thiocya-
nate-phenol-chloroform method [16]. Twenty Wg per lane of total
RNA was used for electrophoresis and transferred to a nylon mem-
brane as previously described [7]. The cDNA probes used were the
HindIII-BamHI fragment (2.3 kb) of human platelet 12-lipoxygenase
cDNA [18] and the human 18S rRNA [17]. Probes were labeled with
[K-32P]dCTP using a megaprime DNA labeling system. The mRNA
levels were calculated on the basis of hybridization signal measured by
Fujix Bio-imaging Analyzer BAS1000 (Fuji Photo Film Co., Tokyo,
Japan), and the mRNA ratio of 12-lipoxygenase to 18S rRNA in each
sample was obtained.
2.6. Construction of luciferase reporter vector
The human 12-lipoxygenase promoter regions of various lengths
were prepared either by restriction enzyme digestion of the genomic
clone for the preparation of pXLO-01, 1 and 3 or by the PCR am-
pli¢cation method for the preparation of pXLO-4-2, 4-3, 5-2, 7-1 and
8, as described previously [19]. The mutants at Sp1 site (SPM) were
constructed by the site-directed mutagenesis method as described [19].
All the DNA fragments were ligated into a luciferase plasmid pXP-1.
SV40 early promoter was obtained from pGL2 control vector (Prom-
ega) digested with BglII and HindIII and ligated with pXP-1 to form
vector SV40-LUC. Vector SV40-pXLO-7-1 was produced by the liga-
tion of SV40 early promoter and vector pXLO-7-1, with the insertion
of SV40 early promoter between the luciferase gene and 12-lipoxyge-
nase promoter region. All the plasmids for transfection were puri¢ed
by the use of Qiagen-tip 100.
2.7. Transfection with lipofectamine and reporter gene assays
A431 cells were replated 36 h before transfection at a density of
3U105 cells in 2 ml of fresh culture medium in a 3.5-cm plastic dish.
For use in transfection, 12.5 Wl of lipofectamine was incubated with
0.5 Wg of pXLO luciferase plasmid and 0.1 Wg of L-galactosidase
plasmid in 1 ml of Opti-MEM medium for 30 min at room temper-
ature, followed by incubation at 37‡C for 24 h. After the change of
Opti-MEM medium to 2 ml of fresh culture medium, cells were in-
cubated for an additional 24 h and then treated with TGF-K. The
luciferase and L-galactosidase activities in cell lysate were determined
as described previously [19].
2.8. Transfection by calcium phosphate method
One day prior to transfection, SL2 cells were plated onto 6-cm
plastic dish at a density of 4.5U106 cells, and transfected by the
calcium phosphate method as described [20]. Every plate received
5 Wg of DNA including 0.5 Wg of pXLO-7-1 luciferase plasmid,
0.5 Wg of L-galactosidase plasmid, and CMV-Sp1 or CMV-Sp3 plas-
mid. Variable amounts of expression plasmids were compensated with
the empty vector pBSSK. Twenty-four h after addition of DNA, the
medium was changed. After another 24 h, cells were washed twice
with phosphate-bu¡ered saline and harvested.
2.9. Gel-shift assays
Nuclear protein extraction and gel-shift assay were performed as
previously described [19]. The binding reaction was performed with
end-labeled oligonucleotide from the 12-lipoxygenase promoter region
from 3224 to 3124 bp and 6 Wg of nuclear extract. Electrophoresis
was performed at a constant 120 V for 3 h. The gel was dried and
autoradiographed.
3. Results
3.1. Stimulation of 12-lipoxygenase expression
TGF-K stimulated the expression of 12-lipoxygenase activ-
ity in a time-dependent manner. The percentages of increase
in the enzyme activity induced by 50 ng/ml TGF-K were 15,
47, 94, 130 and 100% for 5, 7, 9, 14 and 18 h of treatments,
respectively (Fig. 1A). As shown in Fig. 1B, the expression
mRNA was induced by TGF-K. The maximum e¡ect of TGF-
K on the expression of 12-lipoxygenase was approximately
half of the EGF response under the same experimental con-
dition (data not shown).
3.2. 12-Lipoxygenase promoter analysis
Using cells transfected with vector pXLO-01 (32 kb), the
dose-response e¡ect of TGF-K on 12-lipoxygenase gene tran-
scription was studied. A dose-dependent response of TGF-K
was observed, which paralleled with its e¡ect on the enzyme
activity (Fig. 2). In order to study the transcriptional regula-
tion of 12-lipoxygenase gene, cells were transfected with var-
ious pXLO DNA constructs. The e¡ect of TGF-K on the
luciferase activity of these pXLO vectors was studied. The
results are summarized in Fig. 3. The transcriptional activities
of luciferase-bearing vectors pXLO-01 (3951 bp), pXLO-3
Fig. 1. Time-dependent e¡ect of TGF-K on 12-lipoxygenase activity
and mRNA expression. A: Con£uent cells were treated with 50 ng/
ml TGF-K in serum-free medium for 30 min, which were then
switched to TGF-K-free medium for 3^18 h of incubation as indi-
cated. Percentage of the change in 12-lipoxygenase activity induced
by TGF-K is indicated at various time intervals. Results shown rep-
resent the mean þ S.E.M. of three determinations. B: For the deter-
mination of 12-lipoxygenase mRNA expression, cells were treated
with (T) or without (C) 50 ng/ml TGF-K for 30 min, which were
then switched to TGF-K-free medium for 9 h. Expression of 12-lip-
oxygenase mRNA was then determined.
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(3754 bp), pXLO-4-2 (3550 bp), pXLO-5-2 (3378 bp),
pXLO-7-1 (3224 bp), were stimulated by the treatment of
the corresponding transfected cells with 50 ng/ml TGF-K.
The stimulation ratio ranging from 2.8 to 4.6 was obtained
by comparing the luciferase activity in TGF-K-treated cells to
that of the control cells. The stimulation response of TGF-K
was drastically reduced in pXLO-7-2 (3145 bp) and com-
pletely disappeared in pXLO-8 (3100 bp), indicating that a
promoter region ranging from 3224 bp to 3100 bp was im-
portant for the TGF-K-stimulated response of 12-lipoxygenase
expression. Three Sp1 binding sites (3169 to 3161 bp, 3158
to 3150 bp and 3123 to 3114 bp) exist in this region. Plas-
mids with mutated Sp1 binding sites in the promoter region
were constructed by site-directed mutagenesis (Fig. 4A). The
e¡ect of TGF-K on the reporter activity of these constructs is
summarized in Fig. 4B. Among the vectors with single muta-
tion, 0%, 63%, and 43% decrease in TGF-K response were
observed in SPM5, SPM4 and SPM6, respectively. A 73%
decrease was observed in SPM9 with mutation at both up-
stream and downstream of Sp1 site. Plasmids with mutation
at downstream and at the middle of Sp1 site (SPM7 and
SPM8) almost eliminated the luciferase reporter activity in-
duced by TGF-K treatment. These results indicate that the
nucleotide sequences residing at 3123 to 3114 bp and
3158 to 3150 bp, played a critical role in TGF-K-induced
transcription of human 12-lipoxygenase gene.
3.3. Activation of 12-lipoxygenase promoter by Sp1
In an earlier study [19], results of gel mobility shift assay
indicated that proteins extracted from A431 cell nucleus in-
teracting with highly GC-rich Sp1 sites within the promoter
region ranging from 3224 to 3100 bp were mostly due to Sp1
and Sp3. To verify whether Sp1 and Sp3 activate the pro-
moter activity of 12-lipoxygenase gene, vector pXLO-7-1
was transfected into the Sp1-de¢cient Drosophila Schneider
Fig. 2. Dose-dependent e¡ect of TGF-K on 12-lipoxygenase activity
and luciferase reporter activity. For studying the e¡ect of TGF-K
on 12-lipoxygenase activity (closed circles), con£uent cells were
treated with various concentrations of TGF-K in serum-free medium
for 30 min. They were then switched to TGF-K-free medium up to
18 h. 12-Lipoxygenase activity in microsomes of cells was assayed.
For studying the e¡ect of TGF-K on luciferase reporter activity
(open circles), a mixture of 0.5 Wg of pXLO-01 and 0.1 Wg of L-gal-
actosidase plasmid was transfected into A431 cells by the lipofection
method. The transfected cells were treated with various concentra-
tions of TGF-K for 30 min. They were then switched to fresh se-
rum-free medium up to 18 h. The expressions of luciferase and L-
galactosidase activities of cell lysate were determined and normal-
ized. The expression ratio of TGF-K-treated cells to control cells is
indicated. The results shown represent the mean of three determina-
tions.
Fig. 3. E¡ect of TGF-K on the expression of luciferase vectors bearing various lengths of 12-lipoxygenase gene promoter. Luciferase vectors
bearing various lengths of 12-lipoxygenase gene promoter were constructed as indicated. The potential consensus sequences in the 5P-£anking
region are indicated. Abbreviations used are Sp1, Sp1 binding sites; CACCC, CACCC box found in L-globin gene promoters; AP2, AP2 bind-
ing sites; NFUB, binding sites of NFUB; C/EBPL, binding sites for CCAAT/enhancer binding protein; and GATA, GATA box. The transcrip-
tion initiation sites at 355G, 348G and 347A in A431 cells are also indicated. Plasmid transfection was performed as described in Section 2.
The expression ratio of TGF-K-treated cells to control cells is indicated. The results shown represent the mean þ S.E.M. of two to ¢ve determi-
nations.
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SL2 cell line either in the presence or in the absence of Sp1
and Sp3 expression vectors. As shown in Fig. 5, expression of
Sp1 stimulated the activity of 12-lipoxygenase promoter in a
dose-dependent manner, while Sp3 did not show any signi¢-
cant e¡ect. To examine the role of Sp1 binding sequence in
the gene promoter activation by Sp1, an SV40 early promoter,
which contains six Sp1 binding sites located in the 21 bp
repeat region [21], was used. Expression of luciferase activity
driven by SV40 early promoter was close to that of pXLO-1
upon stimulation by the expression of Sp1 (Fig. 6). If these
two promoters were ligated to form a vector SV40-pXLO-7-1,
an addition e¡ect of these two promoters by the Sp1 expres-
sion was observed on the luciferase activity. These results
indicate that the Sp1 binding sites in the promoter of 12-lip-
oxygenase and the SV40 early promoter responded equally
well to Sp1.
3.4. Gel-shift analysis
Binding of the cell nuclear proteins prepared form TGF-K-
treated cells to 12-lipoxygenase gene promoter was analyzed
by gel-shift assay. Since the three major retarded bands de-
pend mainly on Sp1 and Sp3 proteins [19], the binding of the
Sp1 and Sp3 of the cell nuclear extract to the promoter probe
was studied. No change in these two protein-DNA complexes
was found in cells treated with TGF-K for 5 and 9 h, com-
pared with its respective control cells (Fig. 7).
4. Discussion
Several pieces of evidence were provided in this study to
indicate that TGF-K stimulated the expression of 12-lipoxy-
genase mRNA and enzyme activity. TGF-K activated the pro-
moter activity of 12-lipoxygenase gene in the same fashion as
EGF in human epidermoid carcinoma A431 cells. Induction
of 12-lipoxygenase expression by TGF-K was a slow and sus-
tained reaction, which required a lag period of 5^7 h (Fig.
Fig. 4. Analysis of TGF-K-responsive sequence in the 5P-£anking region of 12-lipoxygenase gene. A: Site-directed mutagenesis of Sp1 consensus
sequences in the 5P-£anking region ranging from 3170 to 3110 of 12-lipoxygenase gene. The sequence of wild-type (WT) promoter and mu-
tated nucleotides in mutant constructs are indicated. B: The expression ratio of TGF-K-treated cell to control cells is indicated. The results
shown represent the mean þ S.E.M. of two to ¢ve determinations.
Fig. 5. Dose-response e¡ect of Sp1 and Sp3 on luciferase reporter
activity in SL2 cells. SL2 cells were transfected with 0.5 Wg of
pXLO-7-1 and 0.5 Wg of CMV-L-gal with various amounts of
CMV-Sp1 (close circles) or CMV-Sp3 (open circles) by calcium
phosphate method. The total amount of DNA added was main-
tained at 5 Wg with pBSSK. Cells were harvested 48 h after transfec-
tion. The expression of luciferase and L-galactosidase activity of cell
lysate was determined and normalized. The results shown represent
the mean of three determinations.
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1A). The stimulatory e¡ect of TGF-K on cellular accumula-
tion of 12-lipoxygenase mRNA was at least partly due to the
increase in transcription of 12-lipoxygenase gene. This was
veri¢ed by the luciferase reporter assay. The dose-response
of TGF-K-induced expression of luciferase vector pXLO-7-1
was parallel to that of TGF-K-induced stimulation of 12-lip-
oxygenase activity. In the analysis of promoter regulation, we
identi¢ed previously that the same speci¢c Sp1 consensus sites
residing at 3158 to 3150 bp and 3123 to 3114 bp in the
promoter region were involved in the mediation of EGF in-
duction of the 12-lipoxygenase gene are also responsible for
the basal promoter activity [19]. The same result was also
observed in TGF-K-induced activation of 12-lipoxygenase
promoter in the present study (Figs. 3 and 4).
Sp1 and Sp3 were two major nuclear proteins in A431 cells
which bind to the middle and downstream of Sp1 consensus
sequences in the promoter region of the 12-lipoxygenase gene
[19]. After transient transfection of the expression vectors con-
taining Sp1 and Sp3 in SL2 cells, only Sp1 activated the pro-
moter activity of 12-lipoxygenase gene. Sp3 did not have any
direct e¡ect (Fig. 5). In addition to the activation of the 12-
lipoxygenase promoter, Sp1 also activated an SV40 early pro-
moter containing rich Sp1 binding sites (Fig. 6), which was in
accordance with the EGF e¡ect on the same promoter in
A431 cells [19]. Therefore, nuclear protein Sp1 played a crit-
ical role not only in the basal expression of 12-lipoxygenase
gene, but also in the transcriptional regulation of 12-lipoxy-
genase induced by TGF-K and EGF in A431 cells. Mediation
of promoter activation by Sp1 consensus sites in basal tran-
scription and induction of the cyclin-dependent kinase inhib-
itor p15INK4B expression by transforming growth factor L in
human keratinocyte HaCat cells has also been reported [22]. It
is still unclear how Sp1 mediates the induction of 12-lipoxy-
genase gene transcription by TGF-K and EGF because no
increase in binding between Sp1 and promoter DNA was
observed in gel-shift analysis (Fig. 7). Accumulating evidence
suggests that Sp1 and its protein family regulate the transcrip-
tional machinery through the action of TATA box binding
protein-associated factors [23]. It is possible that some TATA
box binding protein-associated factors could relay the signal
of TGF-K and EGF, which leads to the activation of 12-lip-
oxygenase gene expression in A431 cells.
TGF-K shares about 30% structure similarity with EGF,
including the conservation of all six cysteines [24]. This se-
quence relationship and the presumed formation of three sim-
ilar disul¢de bridges in both molecules provide a molecular
explanation for the interaction of the two growth factors with
the same cellular EGF receptor [25]. They exert similar mito-
genic e¡ect in many cells types [25] including A431 cells [26].
While most biological actions of these factors are in common,
certain di¡erences, usually quantitative, between their e¡ects
have been reported. For the induction of 12-lipoxygenase ex-
pression in A431 cells, the present results suggest that TGF-K
acted similarly as EGF, with the exception that the maximum
stimulatory e¡ect which was only half of that of EGF as we
previously reported [19]. A smaller maximal e¡ect of TGF-K
on 12-lipoxygenase expression could be explained by a lower
a⁄nity to EGF receptor since the a⁄nity of TGF-K to EGF
receptor of A431 cells is about half of that of EGF [26].
Stimulation of the expression of 12-lipoxygenase by TGF-K
in human epidermoid carcinoma A431 cells with an overex-
pression of EGF receptors may provide a possible mechanism
for the explanation of the overexpression of platelet 12-lip-
oxygenase in psoriatic lesion [8].
Acknowledgements: We are greatly indebted to Dr. Shozo Yamamoto
and Dr. Gunstram Suske for their gifts of pXLO and CMV-Sp1
plasmids, respectively. Thanks are also due to Dr. W.M. Kan for
his critical review of this manuscript and to Y.L. Chang for her
secretarial assistance. This work was supported in part by grants
NSC 87-2314-B006-105 and NSC 88-2314-B006-029 from the Nation-
al Science Council of the Republic of China.
Fig. 6. E¡ect of Sp1 on the expression of vectors bearing Sp1 con-
sensus sites in SL2 cells. SL2 cells were cotransfected with 0.5 Wg of
DNA construct bearing Sp1 consensus sites as indicated as well as
with 0.5 Wg of CMV-L-gal and 4 Wg of CMV-Sp1 by calcium phos-
phate method. The total amount of DNA added was maintained at
5 Wg with pBSSK. Cells were harvested 48 h after transfection. The
expression of luciferase and L-galactosidase activity of cell lysate
was determined and normalized. The results shown represent the
mean of three determinations.
Fig. 7. Gel-shift analysis of the nuclear Sp proteins binding to the
12-lipoxygenase gene promoter. Oligonucleotide covering the pro-
moter region from 3224 to 3124 bp was radiolabeled with [K-
32P]dCTP and used as a probe. The probe was incubated with the
nuclear extracts prepared from control cells (lane 1) and cells
treated with 50 ng/ml TGF-K for 5 and 9 h (lanes 2^3).
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